SequelSEC

Aurinia Pharmaceuticals Inc. AUPH

Pharmaceutical Preparations · CIK 0001600620 · Fiscal year ends 1231

Revenue
$321.74M
Fiscal year ended 2026-09-30
Operating income
$156.36M
Fiscal year ended 2026-09-30
Free cash flow
Unavailable
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$1.00BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$7.52Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income3.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue3.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin101.5%97th
Operating margin37.1%97th
Effective tax rate-151.6%6th
R&D / revenue11.5%16th
Gross margin88.5%81th
SBC / revenue5.2%21th
Revenue YoY growth20.4%66th
Current ratio5.25x62th

Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $321.74M and net income of $314.27M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Aurinia Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aurinia Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$321.74M
Cost of revenue$30.16M
Gross profit$291.57M
Operating income$156.36M
Net income$314.27M
Research & development$48.03M
Weighted-average diluted sharesUnavailable
Pretax income$167.12M
Income tax expense-$147.15M
Diluted EPS$2.29
Selling, general & administrativeUnavailable
General & administrative$99.48M
Selling & marketingUnavailable

Balance

Aurinia Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$45.79M
Total assets$825.70M
Current assets$587.89M
Total liabilities$168.18M
Current liabilities$96.00M
Total equity incl. NCI$657.52M
Temporary (mezzanine) equityUnavailable
Inventory$43.73M
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.01M

Cash flow

Aurinia Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow$177.16M
Capital expendituresUnavailable
Investing cash flow-$149.12M
Financing cash flow-$55.08M
Net change in cash-$27.04M
Stock-based compensation$14.82M
Common dividends paidUnavailable
Common share repurchases$74.88M
Depreciation & amortization$19.36M

Derived

Aurinia Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flowUnavailable
Gross margin90.6%
Operating margin48.6%
FCF marginUnavailable
SBC / revenue4.6%
Current ratio6.12x
Revenue YoY growth21.0%
Net margin97.7%
R&D / revenue14.9%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rate-88.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AUPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-30View SEC filing
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-31View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.